Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of U.S. dollars ($)	Three Months Ended September 30, 2022						Nine Months Ended September 30, 2022
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	193	$	193	$	—	$	834	$	561	$	273
License Fee – Over time	65		—		65		192		—		192
Total Drug Products	258		193		65		1,026		561		465
Concentrates Products
Product Sales – Point-in-time	17,953		16,619		1,334		51,035		46,334		4,701
License Fee – Over time	480		480		—		1,436		1,436		—
Total Concentrate Products	18,433		17,099		1,334		52,471		47,770		4,701
Net Revenue	$	18,691	$	17,292	$	1,399	$	53,497	$	48,331	$	5,166

In thousands of U.S. dollars ($)	Three Months Ended September 30, 2021						Nine Months Ended September 30, 2021
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	217	$	217	$	—	$	656	$	656	$	—
License Fee – Over time	62		—		62		179		—		179
Total Drug Products	279		217		62		835		656		179
Concentrates Products
Product Sales – Point-in-time	15,224		13,541		1,683		44,308		39,768		4,540
License Fee – Over time	485		485		—		1,456		1,456		—
Total Concentrate Products	15,709		14,026		1,683		45,764		41,224		4,540
Net Revenue	$	15,988	$	14,243	$	1,745	$	46,599	$	41,880	$	4,719

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of U.S. dollars ($)	September 30, 2022		December 31, 2021
Receivables, which are included in "Trade and other receivables"	$	7,367	$	5,913
Contract liabilities	$	6,729	$	8,157